Palonosetron
- Generic Name
- Palonosetron
- Brand Names
- Akynzeo, Aloxi, Palonosetron Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O
- CAS Number
- 135729-56-5
- Unique Ingredient Identifier
- 5D06587D6R
- Background
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
- Indication
For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
- Associated Conditions
- Nausea caused by Chemotherapy, Post Operative Nausea and Vomiting (PONV), Acute chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 150
- Registration Number
- NCT00828295
- Locations
- 🇷🇺
Federal State Institution St. Petersburg Research Institute of Ear, Throat, Nose and Speech under the Federal Agency for High-Tech Medical Care, St. Petersburg, Russian Federation
🇷🇺State Healthcare Institution 'Regional Pediatric Clinical Hospital', Yaroslavl, Russian Federation
🇺🇦Cherkassy Regional Hospital, Pediatric Surgery Department, Cherkassy, Ukraine
Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 118
- Registration Number
- NCT00687011
Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 59
- Registration Number
- NCT00684463
An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2008-04-25
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 208
- Registration Number
- NCT00666783
- Locations
- 🇨🇳
Xijng Hospital, Xi,an, Shaanxi, China
Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
- Conditions
- Substance-Related Disorders
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 10
- Registration Number
- NCT00661674
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- Duke University
- Target Recruit Count
- 63
- Registration Number
- NCT00636805
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Multi-day Doses in Prevention of Nausea and Emesis
- Conditions
- Myeloma, Plasma-CellLymphoma, Malignant
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00600353
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
- Conditions
- Chemotherapy-induced Nausea and VomitingUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2020-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT00553059
- Locations
- 🇺🇸
University of Texas M.D. Anderson, Houston, Texas, United States
🇺🇸CCOP - Greenville, Greenville, South Carolina, United States
🇺🇸Cancer Research for the Ozarks, Springfield, Missouri, United States
Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting
- Conditions
- NauseaVomitingChemotherapy
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 144
- Registration Number
- NCT00503386
- Locations
- 🇨🇳
Fujian Provincial Tumor Hospital, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Jiangsu Provincial Tumor Hospital, Nanjing, Jiangsu, China
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial
- Conditions
- Nausea
- Interventions
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2015-11-10
- Lead Sponsor
- Joseph Roscoe
- Target Recruit Count
- 1021
- Registration Number
- NCT00475085
- Locations
- 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
🇺🇸CCOP - Kalamazoo, Kalamazoo, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.